Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol

  • Ina Giegling
  • Beatrice Balzarro
  • Stefano Porcelli
  • Martin Schäfer
  • Annette M. Hartmann
  • Marion Friedl
  • Bettina Konte
  • Philipp Krämer
  • Hans-Jürgen Möller
  • Diana De Ronchi
  • Hans H. Stassen
  • Alessandro Serretti
  • Dan Rujescu
Original Paper

Abstract

The present study explores whether ankyrin repeat and kinase domain containing 1 (ANKK1) and dopamine receptor D2 (DRD2) variants could predict efficacy and tolerability of haloperidol in the treatment of psychotic patients. We also attempted to replicate findings in a group of schizophrenic patients from the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) study. Eighty-eight acutely psychotic patients were genotyped for 9 ANKK1 and 27 DRD2 SNPs. Treatment efficacy and tolerability were assessed using the Positive and Negative Symptoms Scale and the Udvalg for Kliniske Undersogelser side effects rating scales, respectively. Multivariate analyses were employed to test possible influences of single-nucleotide polymorphisms on clinical and safety variables. Analysis of haplotypes was also performed. Outcomes in the replication sample were response versus nonresponse and the presence versus absence of motor side effects at 1 month of treatment. rs2242592 within ANKK1 gene and rs1124493 within DRD2 gene were associated with clinical improvement (p = 0.008 and p = 0.001, respectively). Results were confirmed in the allelic analysis. Three haplotype blocks, one among ANKK1 and two among DRD2 gene were associated with better clinical improvement. Our results were not replicated in the CATIE sample, although rs11604671, which is in strong linkage disequilibrium with rs2242592, was associated with response in the replication sample. Our findings support a possible role of ANKK1 and DRD2 variability on haloperidol efficacy. However, due to the discrepancies between the results in the two samples, our results need further validation.

Keywords

Pharmacogenetics Schizophrenia Antipsychotics Gene Haloperidol 

Supplementary material

406_2012_348_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 15 kb)
406_2012_348_MOESM2_ESM.docx (14 kb)
Supplementary material 2 (DOCX 13 kb)
406_2012_348_MOESM3_ESM.docx (15 kb)
Supplementary material 3 (DOCX 14 kb)
406_2012_348_MOESM4_ESM.docx (12 kb)
Supplementary material 4 (DOCX 11 kb)
406_2012_348_MOESM5_ESM.docx (11 kb)
Supplementary material 5 (DOCX 11 kb)

References

  1. 1.
    Tandon R, Keshavan MS, Nasrallah HA (2008) Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102(1–3):1–18PubMedCrossRefGoogle Scholar
  2. 2.
    Lennertz L, Quednow BB, Benninghoff J, Wagner M, Maier W, Mossner R (2011) Impact of TCF4 on the genetics of schizophrenia. Eur Arch Psychiatry Clin Neurosci 261(Suppl 2):S161–S165PubMedCrossRefGoogle Scholar
  3. 3.
    Arranz MJ, Rivera M, Munro JC (2010) Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 25(11):933–969CrossRefGoogle Scholar
  4. 4.
    Crisafulli C, Chiesa A, Han C, Lee SJ, Park MH, Balzarro B, Andrisano C, Patkar AA, Pae CU, Serretti A (2011) Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. Eur Arch Psychiatry Clin Neurosci 262(3):199–205Google Scholar
  5. 5.
    Mossner R, Schuhmacher A, Wagner M, Lennertz L, Steinbrecher A, Quednow BB, Rujescu D, Rietschel M, Maier W (2011) The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms. Eur Arch Psychiatry Clin Neurosci 262(3):193–197Google Scholar
  6. 6.
    Tiwari AK, Zai CC, Muller DJ, Kennedy JL (2010) Genetics in schizophrenia: where are we and what next? Dialogues Clin Neurosci 12(3):289–303PubMedGoogle Scholar
  7. 7.
    Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6(4):577–582PubMedCrossRefGoogle Scholar
  8. 8.
    Jonsson EG, Nothen MM, Neidt H, Forslund K, Rylander G, Mattila-Evenden M, Asberg M, Propping P, Sedvall GC (1999) Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr Res 40(1):31–36PubMedCrossRefGoogle Scholar
  9. 9.
    Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L (2005) Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 376(1):1–4PubMedCrossRefGoogle Scholar
  10. 10.
    Malhotra AK (2004) Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain. Neurotox Res 6(1):51–56PubMedCrossRefGoogle Scholar
  11. 11.
    Tanaka T, Igarashi S, Onodera O, Tanaka H, Fukushima N, Takahashi M, Kameda K, Tsuji S, Ihda S (1996) Lack of association between dopamine D2 receptor gene Cys311 variant and schizophrenia. Am J Med Genet 67(2):208–211PubMedCrossRefGoogle Scholar
  12. 12.
    Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH (2004) Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol (CINP) 7(4):461–470CrossRefGoogle Scholar
  13. 13.
    Shaikh S, Collier D, Arranz M, Ball D, Gill M, Kerwin R (1994) DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343(8904):1045–1046PubMedGoogle Scholar
  14. 14.
    Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205–216PubMedCrossRefGoogle Scholar
  15. 15.
    Hirvonen J, Aalto S, Lumme V, Nagren K, Kajander J, Vilkman H, Hagelberg N, Oikonen V, Hietala J (2003) Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride. Nucl Med Commun 24(12):1207–1214PubMedCrossRefGoogle Scholar
  16. 16.
    Lawford BR, Young RM, Swagell CD, Barnes M, Burton SC, Ward WK, Heslop KR, Shadforth S, van Daal A, Morris CP (2005) The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia. Schizophr Res 73(1):31–37PubMedCrossRefGoogle Scholar
  17. 17.
    Monakhov M, Golimbet V, Abramova L, Kaleda V, Karpov V (2008) Association study of three polymorphisms in the dopamine D2 receptor gene and schizophrenia in the Russian population. Schizophr Res 100(1–3):302–307PubMedCrossRefGoogle Scholar
  18. 18.
    Ponce G, Perez-Gonzalez R, Aragues M, Palomo T, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J (2009) The ANKK1 kinase gene and psychiatric disorders. Neurotox Res 16(1):50–59PubMedCrossRefGoogle Scholar
  19. 19.
    Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Otani K, Furukori H, Kaneko S, Inoue Y (2001) Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report. Eur Arch Psychiatry Clin Neurosci 251(2):57–59PubMedCrossRefGoogle Scholar
  20. 20.
    Noble EP (2003) D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 116B(1):103–125PubMedCrossRefGoogle Scholar
  21. 21.
    Pohjalainen T, Rinne JO, Nagren K, Syvalahti E, Hietala J (1998) Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 155(6):768–773PubMedGoogle Scholar
  22. 22.
    Thompson TL, Moss RL (1997) Modulation of mesolimbic dopaminergic activity over the rat estrous cycle. Neurosci Lett 229(3):145–148PubMedCrossRefGoogle Scholar
  23. 23.
    Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, Moller HJ (2001) Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 158(5):802–804PubMedCrossRefGoogle Scholar
  24. 24.
    Shen YC, Chen SF, Chen CH, Lin CC, Chen SJ, Chen YJ, Luu SU (2009) Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 43(6):600–606PubMedCrossRefGoogle Scholar
  25. 25.
    Suzuki A, Kondo T, Mihara K, Furukori H, Nagashima U, Ono S, Otani K, Kaneko S (2000) Association between Taq1 a dopamine D2 receptor polymorphism and psychopathology of schizophrenia in Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry 24(7):1105–1113PubMedCrossRefGoogle Scholar
  26. 26.
    Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N (2003) Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 3(6):356–361PubMedCrossRefGoogle Scholar
  27. 27.
    Neville MJ, Johnstone EC, Walton RT (2004) Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23(6):540–545PubMedCrossRefGoogle Scholar
  28. 28.
    Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29(1):15–31PubMedCrossRefGoogle Scholar
  29. 29.
    Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276PubMedCrossRefGoogle Scholar
  30. 30.
    Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334:1–100CrossRefGoogle Scholar
  31. 31.
    Chen L, Ascher-Svanum H, Stauffer V, Kinon BJ, Kollack-Walker S, Ruberg S (2009) Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res 113(1):34–40PubMedCrossRefGoogle Scholar
  32. 32.
    Obermeier M, Schennach-Wolff R, Meyer S, Moller HJ, Riedel M, Krause D, Seemuller F (2011) Is the PANSS used correctly? A systematic review. BMC Psychiatry 11:113PubMedCrossRefGoogle Scholar
  33. 33.
    Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G (2005) Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res 77(2–3):119–128PubMedCrossRefGoogle Scholar
  34. 34.
    Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676PubMedCrossRefGoogle Scholar
  35. 35.
    Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11–19CrossRefGoogle Scholar
  36. 36.
    Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D (2009) Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol (Clifton, NJ) 578:307–343CrossRefGoogle Scholar
  37. 37.
    Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, Swan GE, Rutter J, Bertelsen S, Fox L, Fugman D, Goate AM, Hinrichs AL, Konvicka K, Martin NG, Montgomery GW, Saccone NL, Saccone SF, Wang JC, Chase GA, Rice JP, Ballinger DG (2007) Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16(1):24–35PubMedCrossRefGoogle Scholar
  38. 38.
    Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL (2008) Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13(6):570–584PubMedCrossRefGoogle Scholar
  39. 39.
    Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125(1–2):279–284PubMedCrossRefGoogle Scholar
  40. 40.
    Barrett JC (2009) Haploview: visualization and analysis of SNP genotype data. Cold Spring Harbor protocols 2009 (10): pdb ip71Google Scholar
  41. 41.
    Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559–575PubMedCrossRefGoogle Scholar
  42. 42.
    Dubertret C, Bardel C, Ramoz N, Martin PM, Deybach JC, Ades J, Gorwood P, Gouya L (2010) A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. Prog Neuropsychopharmacol Biol Psychiatry 34(3):492–499PubMedCrossRefGoogle Scholar
  43. 43.
    Houston J, Dharia S, Bishop JR, Ellingrod VL, Fijal B, Jacobson JG, Hoffmann VP (2011) Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res 187(1–2):74–79PubMedCrossRefGoogle Scholar
  44. 44.
    Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, van Harten PN (2012) Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One 7(5):e36561PubMedCrossRefGoogle Scholar
  45. 45.
    Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D, Malhotra AK (2010) DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 20(9):569–572PubMedCrossRefGoogle Scholar
  46. 46.
    Cordeiro Q, Siqueira-Roberto J, Zung S, Vallada H (2009) Association between the DRD2-141C insertion/deletion polymorphism and schizophrenia. Arq Neuropsiquiatr 67(2A):191–194PubMedCrossRefGoogle Scholar
  47. 47.
    Parsons MJ, Mata I, Beperet M, Iribarren-Iriso F, Arroyo B, Sainz R, Arranz MJ, Kerwin R (2007) A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate. Psychiatr Genet 17(3):159–163PubMedCrossRefGoogle Scholar
  48. 48.
    Sullivan PF (2007) Spurious genetic associations. Biol Psychiatry 61(10):1121–1126PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Ina Giegling
    • 1
  • Beatrice Balzarro
    • 2
  • Stefano Porcelli
    • 2
  • Martin Schäfer
    • 1
    • 5
  • Annette M. Hartmann
    • 1
  • Marion Friedl
    • 1
  • Bettina Konte
    • 1
  • Philipp Krämer
    • 1
  • Hans-Jürgen Möller
    • 1
  • Diana De Ronchi
    • 2
  • Hans H. Stassen
    • 3
  • Alessandro Serretti
    • 2
  • Dan Rujescu
    • 1
    • 4
  1. 1.Department of PsychiatryLudwig Maximilians UniversityMunichGermany
  2. 2.Institute of PsychiatryUniversity of BolognaBolognaItaly
  3. 3.Psychiatric University HospitalZurichSwitzerland
  4. 4.Department of PsychiatryUniversity of HalleHalleGermany
  5. 5.Kliniken Essen MitteEssenGermany

Personalised recommendations